Urine inhibitory titers against resistant Escherichia coli isolates after oral amoxicillin-sulbactam.
暂无分享,去创建一个
J. Casellas | M. Visser | H. Arenoso | J. Soutric | G. Tomé | N. MacDougall | H. Cohen
[1] J. Casellas,et al. Erradicación de Escherichia coli de la orina vesical por amoxicilina-sulbactam. Actividad intrínseca del inhibidor , 2001 .
[2] H. Sader,et al. Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening. , 2000, Infectious disease clinics of North America.
[3] C. Bantar,et al. A Pharmacodynamic Model to Support a 12-Hour Dosing Interval for Amoxicillin/Sulbactam, a Novel Oral Combination, in the Treatment of Community-Acquired Lower Respiratory Tract Infections , 2000, Journal of chemotherapy.
[4] M. Galas,et al. Pharmacokinetics and Pharmacodynamics of Amoxicillin-Sulbactam, a Novel Aminopenicillin–β-Lactamase Inhibitor Combination, against Escherichia coli , 1999, Antimicrobial Agents and Chemotherapy.
[5] D. Livermore. beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.
[6] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[7] G. Källenius,et al. [Pathogenesis of urinary tract infections]. , 1979, Läkartidningen.
[8] W. Craig,et al. Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .
[9] J. Casellas,et al. The sleeping giant. Antimicrobial resistance. , 1994, Infectious disease clinics of North America.
[10] Casellas Jm,et al. The sleeping giant. Antimicrobial resistance. , 1994 .